ReproCell Inc
TSE:4978
ReproCell Inc
Accounts Payable
ReproCell Inc
Accounts Payable Peer Comparison
Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ReproCell Inc
TSE:4978
|
Accounts Payable
¥170.1m
|
CAGR 3-Years
5%
|
CAGR 5-Years
13%
|
CAGR 10-Years
13%
|
|
GNI Group Ltd
TSE:2160
|
Accounts Payable
¥2.1B
|
CAGR 3-Years
104%
|
CAGR 5-Years
27%
|
CAGR 10-Years
49%
|
|
PeptiDream Inc
TSE:4587
|
Accounts Payable
¥3B
|
CAGR 3-Years
197%
|
CAGR 5-Years
103%
|
CAGR 10-Years
77%
|
|
Takara Bio Inc
TSE:4974
|
Accounts Payable
¥1.5B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
J
|
Japan Tissue Engineering Co Ltd
TSE:7774
|
Accounts Payable
¥83.6m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
1%
|
S
|
StemRIM Inc
TSE:4599
|
Accounts Payable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is ReproCell Inc's Accounts Payable?
Accounts Payable
170.1m
JPY
Based on the financial report for Mar 31, 2024, ReproCell Inc's Accounts Payable amounts to 170.1m JPY.
What is ReproCell Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
13%
Over the last year, the Accounts Payable growth was -18%. The average annual Accounts Payable growth rates for ReproCell Inc have been 5% over the past three years , 13% over the past five years , and 13% over the past ten years .